A Study of Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection on Vancomycin Resistant Enterococci Status of Patients

Overview

About this study

The purpose of this study is to evaluate if Vancomycin Resistant Enterococci (VRE) can be eradicated in patients with Clostridium Difficile infection (CDI) through treatment with Fecal Microbiota Transplantation (FMT) when FMT is being done to treat recurrent CDI rather than VRE.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients > 18 years age, undergoing fecal microbiota transplantation (FMT) for recurrent clostridium difficile infection (CDI)

Exclusion Criteria:

Patients who will not give consent for stool specimen collection

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Sahil Khanna, M.B.B.S.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Sahil Khanna, M.B.B.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials